ROCKVILLE, Md.–(BUSINESS WIRE)– Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it has appointed Steve Sang Young Park and Robert V. Ahlgren as new members to its Board of Directors, expanding the board to twelve members.
“We are pleased to welcome Steve and Robert to Immunomic’s Board. Our scientific platform, financial acumen and growth strategies are strengthened by their wealth of knowledge and leadership experience,” commented Dr. William Hearl, CEO of ITI. “Each brings deep and diverse expertise across global financial markets and large healthcare companies that will be meaningful to us as we advance our immunotherapy pipeline and strategic vision.”
New Board Member Biographies:
Steve Sang Yong Park most recently served as Senior Managing Director and Chairman of Korea Equity Capital Solutions for Macquarie Group located in Seoul, Korea, a position he held until June 2021. In such role, he was responsible for equity capital markets activities for Macquarie Group in Korea. Prior to holding this position, he worked for Macquarie Group in various leadership positions, including Country Head of Macquarie Group Korea, Head of Macquarie Capital and Head of Securities Responsibilities since October 2014. Prior to October 2014, since April 1996, Mr. Park held various leadership positions with other investment banks in Korea, including Goldman Sachs (Asia) LLC, Credit Suisse Securities LTD, NatWest Markets, Morgan Stanley & Co. International Limited and Bankers Trust. He currently serves on the Board of Directors of GS Global and on the Board of Trustees of East Asia Institute. He received a B.A. in Political Economy of Industrial Societies from the University of California in 1990 and a Master’s in International Affairs and Certificate of Asian Studies from Columbia University in 1992.
Robert V. Ahlgren brings over 30 years of management and leadership experience in the scientific laboratory supply and diagnostic manufacturing industries to ITI. Most recently, he served as Group President Global Distribution for a division of Fisher Scientific from 2004 until 2006, when he retired. Prior to his last role with Fisher Scientific, Mr. Ahlgren served in leadership positions at Apogent Technologies, where he served as chief operating officer, Murex, Baxter Healthcare, American Hospital Supply and Corning. Mr. Ahlgren earned a B.S. honors degree in Health Care Administration from Ithaca College. Mr. Ahlgren currently is involved with two angel investment funds, Tamiami and New World Angel Funds.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, and producing antigen-derived antibodies as biologics. In 2020, an investment of over $77M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline. The Company has built a pipeline from UNITE with four wholly owned oncology programs, the lead of which is in a Phase 2 clinical study for Glioblastoma Multiforme (GBM). ITI has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005006/en/